Onesource Specialty Pharma Limited Share Price & Analysis
₹1,651.2▼ -2.52%Updated 21 Jul 2026, 05:01 pm IST
LTP
₹1,651.2
-2.52%
Open
₹—
High
₹1,705
Low
₹1,637
Close
₹1,651.2
52W High
₹2,026
52W Low
₹1,057
Volume
188K
Lot Size
1
Sector
Healthcare
Market Cap
₹19K Cr
Face Value
₹1
Mid CapNIFTY 500
Price Chart
Fundamentals
P/E
—
Sector P/E
54.4
P/B
3.53
EPS
₹-6.43
ROE
-1.09%
ROCE
0.57%
D/E Ratio
0.22
Div Yield
0%
Book Value
₹509
+
Strengths
- ✓Low debt relative to equity (D/E 0.2x)
−
Concerns
- ✗Currently loss-making (EPS ₹-6.4)
- ✗Negative return on equity (ROE -1.1%)
- ✗Low capital efficiency (ROCE 0.6%)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
ONESOURCE · as of Mar 2026
Promoters30.48%▲0.55
FII17.50%▼1.74
DII20.61%▲1.81
Public31.40%▼0.61
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 37.76% | 34.25% | 29.78% | 29.77% | 29.93% | 30.48% |
| FII | 17.44% | 18.54% | 18.69% | 19.39% | 19.24% | 17.50% |
| DII | 12.56% | 18.03% | 18.09% | 18.48% | 18.80% | 20.61% |
| Public | 32.24% | 29.17% | 33.42% | 32.34% | 32.01% | 31.40% |
Corporate Events
To consider and approve the unaudited financial results for the period ended Jun 30, 2026
Results23 Jul 2026
Latest News
All news →OneSource partners with Formycon for biosimilars manufacturing
*OneSource partners with Formycon for biosimilars manufacturing*. Onesource Specialty Pharma has entered a strategic manufacturing partnership with Germany’s Formycon AG to produce biosimilars. The collaboration aims to leverage Formycon’s technology and Onesource’s production capabilities. **No financial terms** of the deal were disclosed. 📊 *STOCKS:* ONESOURCE | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Biosimilars
NSE Filing14 Jul
Onesource Specialty Pharma files regulatory update under SEBI norms
*Onesource Specialty Pharma files regulatory disclosure under SEBI LODR.* This is a routine update as per Regulation 30, indicating compliance with listing obligations. No financial or operational impact evident from the filing. Investors await further details if any material developments follow. 📊 *STOCKS:* ONESOURCE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #regulatory
NSE Filing9 Jul
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹428.22 Cr ▲47.5% | ₹290.34 Cr ▼22.7% | ₹375.76 Cr ▲14.8% | ₹327.27 Cr ▼23.2% | ₹425.95 Cr ▲8.5% | ₹392.56 Cr ▲17.5% | ₹334.05 Cr ▲14.3% | ₹292.29 Cr |
| Op. Profit | ₹91.91 Cr ▲430.7% | ₹17.32 Cr ▼83.7% | ₹106.49 Cr ▲20.4% | ₹88.48 Cr ▼51.5% | ₹182.51 Cr ▲28.6% | ₹141.88 Cr ▲83.5% | ₹77.3 Cr ▲20.2% | ₹64.29 Cr |
| OPM | 21.5% ▲259.5% | 6.0% ▼78.9% | 28.3% ▲4.8% | 27.0% ▼36.9% | 42.9% ▲18.6% | 36.1% ▲56.2% | 23.1% ▲5.2% | 22.0% |
| Net Profit | ₹4.6 Cr ▲105.2% | ₹-88.7 Cr ▼945.6% | ₹10.49 Cr ▲5621.1% | ₹-0.19 Cr ▼100.2% | ₹98.5 Cr ▲243.1% | ₹-68.85 Cr ▼63.6% | ₹-42.08 Cr ▼658.2% | ₹-5.55 Cr |
| EPS (₹) | 0.4 ▲105.2% | -7.74 ▼941.3% | 0.92 ▲4700.0% | -0.02 ▼100.2% | 8.61 ▲243.0% | -6.02 | — | — |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Revenue | ₹1.4K Cr ▼1.6% | ₹1.4K Cr ▲740.1% | ₹172 Cr ▲341.0% | ₹39 Cr ▼70.5% | ₹132 Cr ▲528.6% | ₹21 Cr |
| Expenses | ₹1.1K Cr ▲14.2% | ₹978 Cr ▲285.0% | ₹254 Cr ▲27.6% | ₹199 Cr ▼13.1% | ₹229 Cr ▲146.2% | ₹93 Cr |
| Op. Profit | ₹304 Cr ▼34.9% | ₹467 Cr ▲669.5% | ₹-82 Cr ▲49.1% | ₹-161 Cr ▼66.0% | ₹-97 Cr ▼36.6% | ₹-71 Cr |
| OPM | 21.0% ▼34.4% | 32.0% ▲166.7% | -48.0% ▲88.4% | -415.0% ▼468.5% | -73.0% ▲78.1% | -334.0% |
| Other Income | ₹5 Cr ▲105.3% | ₹-94 Cr ▲34.3% | ₹-143 Cr ▲72.8% | ₹-526 Cr ▼13250.0% | ₹4 Cr ▲300.0% | ₹1 Cr |
| Interest | ₹122 Cr ▼26.5% | ₹166 Cr ▲86.5% | ₹89 Cr ▲85.4% | ₹48 Cr ▼29.4% | ₹68 Cr ▲325.0% | ₹16 Cr |
| Depreciation | ₹279 Cr ▲1.8% | ₹274 Cr ▲260.5% | ₹76 Cr ▲15.2% | ₹66 Cr ▼5.7% | ₹70 Cr ▲105.9% | ₹34 Cr |
| PBT | ₹-92 Cr ▼35.3% | ₹-68 Cr ▲82.6% | ₹-391 Cr ▲51.1% | ₹-800 Cr ▼246.3% | ₹-231 Cr ▼90.9% | ₹-121 Cr |
| Tax % | -20.0% ▲72.6% | -73.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Profit | ₹-74 Cr ▼311.1% | ₹-18 Cr ▲95.4% | ₹-391 Cr ▲51.1% | ₹-800 Cr ▼246.3% | ₹-231 Cr ▼90.9% | ₹-121 Cr |
| EPS (₹) | -6.44 ▼310.2% | -1.57 | — | — | — | — |
| Div Payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Liabilities | ||||||
| Equity Capital | ₹11 Cr ▲0.0% | ₹11 Cr ▲175.0% | ₹4 Cr ▲0.0% | ₹4 Cr ▲33.3% | ₹3 Cr ▲50.0% | ₹2 Cr |
| Reserves | ₹5.8K Cr ▼0.8% | ₹5.9K Cr ▲1397.2% | ₹392 Cr ▼49.8% | ₹781 Cr ▼22.6% | ₹1.0K Cr ▲30.4% | ₹774 Cr |
| Borrowings | ₹1.5K Cr ▲94.8% | ₹772 Cr ▲37.4% | ₹562 Cr ▼35.0% | ₹864 Cr ▼25.1% | ₹1.2K Cr ▲199.0% | ₹386 Cr |
| Other Liabilities | ₹875 Cr ▼12.9% | ₹1.0K Cr ▲114.7% | ₹468 Cr ▲28.2% | ₹365 Cr ▲32.2% | ₹276 Cr ▲187.5% | ₹96 Cr |
| Total Liabilities | ₹8.2K Cr ▲7.2% | ₹7.7K Cr ▲437.0% | ₹1.4K Cr ▼29.2% | ₹2.0K Cr ▼17.5% | ₹2.4K Cr ▲94.1% | ₹1.3K Cr |
| Assets | ||||||
| Fixed Assets | ₹6.2K Cr ▲1.9% | ₹6.1K Cr ▲608.9% | ₹863 Cr ▼36.6% | ₹1.4K Cr ▲10.6% | ₹1.2K Cr ▲94.5% | ₹633 Cr |
| CWIP | ₹314 Cr ▲44.0% | ₹218 Cr ▲16.0% | ₹188 Cr ▼43.7% | ₹334 Cr ▼31.8% | ₹490 Cr ▲13.7% | ₹431 Cr |
| Investments | ₹16 Cr ▲0.0% | ₹16 Cr ▼20.0% | ₹20 Cr ▲400.0% | ₹4 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹1.6K Cr ▲26.3% | ₹1.3K Cr ▲266.6% | ₹356 Cr ▲13.4% | ₹314 Cr ▼56.5% | ₹722 Cr ▲270.3% | ₹195 Cr |
| Total Assets | ₹8.2K Cr ▲7.2% | ₹7.7K Cr ▲437.0% | ₹1.4K Cr ▼29.2% | ₹2.0K Cr ▼17.5% | ₹2.4K Cr ▲94.1% | ₹1.3K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Operating CF | ₹9 Cr ▲113.2% | ₹-68 Cr ▲36.4% | ₹-107 Cr ▲34.4% | ₹-163 Cr ▲60.8% | ₹-416 Cr ▼252.5% | ₹-118 Cr |
| Investing CF | ₹-495 Cr ▼146.3% | ₹-201 Cr ▼139.3% | ₹511 Cr ▲851.5% | ₹-68 Cr ▲90.2% | ₹-692 Cr ▼234.3% | ₹-207 Cr |
| Financing CF | ₹359 Cr ▼12.9% | ₹412 Cr ▲205.4% | ₹-391 Cr ▼431.4% | ₹118 Cr ▼89.8% | ₹1.2K Cr ▲205.0% | ₹381 Cr |
| Net Cash Flow | ₹-127 Cr ▼188.8% | ₹143 Cr ▲1000.0% | ₹13 Cr ▲111.6% | ₹-112 Cr ▼307.4% | ₹54 Cr ▼3.6% | ₹56 Cr |
| Free Cash Flow | ₹-561 Cr ▼186.2% | ₹-196 Cr ▼14.6% | ₹-171 Cr ▲17.4% | ₹-207 Cr ▲80.7% | ₹-1.1K Cr ▼229.5% | ₹-325 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Debtor Days | 177d ▲68.6% | 105d ▼10.3% | 117d ▲225.0% | 36d ▼44.6% | 65d ▲71.1% | 38d |
| Inventory Days | 360d ▲62.2% | 222d ▼14.0% | 258d ▼58.0% | 615d ▼65.9% | 1805d ▲1974.7% | 87d |
| Days Payable | 307d ▲108.8% | 147d ▼9.8% | 163d ▼61.2% | 420d ▲2.4% | 410d ▼46.2% | 762d |
| Cash Conv. Cycle | 230d ▲27.8% | 180d ▼15.1% | 212d ▼8.6% | 232d ▼84.1% | 1461d ▲329.4% | -637d |
| Working Capital Days | -29d ▲50.0% | -58d ▲93.4% | -877d ▲87.0% | -6745d ▼422.5% | -1291d ▲46.0% | -2392d |
| ROCE | 1.0% ▼83.3% | 6.0% ▲150.0% | -12.0% ▲0.0% | -12.0% ▼20.0% | -10.0% | — |
Source: Screener.in · Lower days = better efficiency
Related Analysis
Frequently Asked Questions
What is Onesource Specialty Pharma Limited share price today?▾
Onesource Specialty Pharma Limited (ONESOURCE) is currently trading at ₹1,651.2 on NSE, down 2.52% as of the last market session. Prices update daily after market close on MarketNetra.
Is Onesource Specialty Pharma Limited available in F&O (Futures & Options)?▾
Yes, Onesource Specialty Pharma Limited (ONESOURCE) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Onesource Specialty Pharma Limited 52-week high and low?▾
Onesource Specialty Pharma Limited's 52-week high is ₹2,026 and the 52-week low is ₹1,057. The current price of ₹1,651.2 is 18.5% below the 52W high.
What is Onesource Specialty Pharma Limited P/E ratio?▾
Onesource Specialty Pharma Limited's P/E ratio and other fundamental metrics including P/B, ROE, and ROCE are available on the overview page. Data is sourced weekly from Screener.in.
How to trade Onesource Specialty Pharma Limited options?▾
Onesource Specialty Pharma Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade ONESOURCE options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.